RxDoctor Payments Data

Mateja de Leonni Stanonik, MD

Neurology · Tucson, AZNPI 1730344102

Payments from drug & device makers

$17,116in general payments, 2019–2025

Across 784 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • AstraZeneca$763
  • Sanofi$736
  • Jazz Pharmaceuticals Inc.$692
  • Lilly USA, LLC$637
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$16,24595%
  • Education$8715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$2,239
UCB, Inc.68$1,336
AstraZeneca(2 entities)28$763
Sanofi34$736
Jazz Pharmaceuticals Inc.25$692
Lilly USA, LLC32$637
Novartis29$626
Eisai Inc.34$579
Lundbeck LLC23$559
Harmony Biosciences LLC18$512
Amgen(2 entities)23$478
Argenx US, Inc.18$461
Biogen28$457
Teva Pharmaceuticals USA, Inc.22$442
EMD Serono, Inc.16$379
Cadwell Industries, Inc1$350
Amneal Pharmaceuticals LLC17$290
Upsher-smith Laboratories LLC11$283
Boston Scientific14$278
SK Life Science, Inc.10$272
Abbott12$242
Neurocrine Biosciences, Inc.10$226
CSL Behring9$223
Mallinckrodt Hospital Products Inc.6$221
Bristol Myers Squibb10$219
Johnson & Johnson(2 entities)7$210
Genentech USA, Inc.9$208
Pfizer12$204
Corium, LLC10$191
Neurelis, Inc.7$182
Supernus Pharmaceuticals, Inc.12$176
Sunovion Pharmaceuticals Inc.10$160
Axsome Therapeutics, Inc.6$155
Impel Pharmaceuticals Inc.8$144
Vanda Pharmaceuticals Inc.7$141
Stryker1$137
Avadel CNS Pharmaceuticals, LLC5$132
Merz Pharmaceuticals, LLC4$129
Biohaven Pharmaceuticals, Inc.6$121
GE HealthCare6$101
Kyowa Kirin, Inc.4$99
Otsuka America Pharmaceutical, Inc.4$88
Sumitomo Pharma America, Inc.5$74
Takeda Pharmaceuticals U.S.A., Inc.3$65
Grifols USA, LLC3$64
Biohaven Pharmaceutical Holding Company Ltd.3$61
Tanabe Pharma America, Inc.3$56
Impel Pharmaceuticals LLC3$56
Scilex Pharmaceuticals Inc.3$50
Aucta Pharmaceuticals, Inc.3$50
Acadia Pharmaceuticals Inc2$42
Avanir Pharmaceuticals, Inc.2$41
Philips North America LLC1$38
Neuropace, Inc.2$37
Banner Life Sciences, LLC2$36
Avion Pharmaceuticals2$35
Medtronic1$34
Arbor Pharmaceuticals, Inc.2$33
Tonix Medicines, Inc.1$29
Collegium Pharmaceutical, Inc.2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,116 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$519,247
Medicare patients
475
Services billed
22,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$244,190
Emgality PenGalcanezumab-Gnlm75$125,226
BotoxOnabotulinumtoxina65$117,161
Nurtec OdtRimegepant Sulfate56$94,142
NuplazidPimavanserin Tartrate12$59,185
RytaryCarbidopa/Levodopa89$57,650
Ajovy AutoinjectorFremanezumab-Vfrm27$34,950
NuedextaDextromethorphan Hbr/Quinidine14$30,657
Rasagiline Mesylate143$26,797
QuliptaAtogepant21$26,533
UbrelvyUbrogepant21$25,817
NamzaricMemantine Hcl/Donepezil Hcl20$16,172
Memantine Hcl598$14,049
Gabapentin424$9,406
Diclofenac Potassium15$7,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy, Namzaric$2,239$185,684127 claims
PfizerNurtec Odt$204$94,14256 claims
Acadia Pharmaceuticals IncNuplazid$42$59,18512 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$290$58,940108 claims
Avanir Pharmaceuticals, Inc.Nuedexta$41$30,65714 claims
Upsher-smith Laboratories LLCTopiramate$283$926105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →